Log In
BCIQ
Print this Print this
 

SG273

  Manage Alerts
Collapse Summary General Information
Company SomaGenics Inc.
DescriptionSynthetic short interfering RNAs (siRNA) targeting conserved regions within the Internal Ribosome Entry Site (IRES) of the HCV genome that are formulated with lipid nanoparticle siRNA delivery technology
Molecular Target
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPreclinical
Standard IndicationHepatitis C virus (HCV)
Indication DetailsTreat HCV infection
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today